ABO haemolytic disease of the newborn is a blood disorder that can affect babies in their first days of life, occurring when a mother’s immune system produces antibodies that attack her baby’s red blood cells due to a mismatch in blood type.

Understanding ABO Haemolytic Disease of the Newborn

ABO haemolytic disease of the newborn, often called ABO HDN, happens when a mother and her baby have incompatible blood types from the ABO blood group system. The term “haemolytic” refers to the breaking down of red blood cells, which normally circulate in the body for around 120 days. In babies with this condition, these vital cells are destroyed much faster than they should be, leading to various health problems that require careful monitoring and sometimes treatment.^[1]

This condition is notably different from Rh disease, another form of blood incompatibility between mother and baby. Unlike Rh disease, which typically becomes worse with each pregnancy, ABO HDN can strike during a first pregnancy. In fact, about half of all ABO HDN cases occur in firstborn babies. The condition also tends not to worsen in subsequent pregnancies, making it somewhat more predictable than other forms of blood group incompatibility.^[2]

The disorder occurs when maternal antibodies cross the placenta and enter the baby’s bloodstream, where they recognize the baby’s red blood cells as foreign invaders. These antibodies then attack and destroy the baby’s red blood cells, triggering a cascade of problems including anemia (a low red blood cell count) and jaundice (yellowing of the skin caused by buildup of a substance called bilirubin).^[1]

How Common Is ABO Haemolytic Disease of the Newborn

ABO haemolytic disease of the newborn is actually quite uncommon when you consider how frequently blood type mismatches occur between mothers and babies. For Caucasian populations, approximately one-fifth of all pregnancies involve some degree of ABO incompatibility between the fetus and mother. However, only a very small minority of these cases develop into symptomatic ABO HDN that requires medical attention.^[2]

The condition primarily affects babies born to mothers with type O blood. This is because mothers with type O blood are more likely to produce antibodies of a specific type called IgG, which can cross the placenta and reach the baby. The more common type of antibody, called IgM, is too large to pass through the placenta and therefore doesn’t affect the baby.^[2]

While cases are most common in mothers with blood type O, there have been rare documented cases of ABO HDN occurring in infants born to mothers with blood types A and B. These instances are unusual but demonstrate that the condition, though uncommon, can occur in different scenarios.^[2]

In the United States, advances in early detection and treatment have helped limit hemolytic disease of the newborn overall to approximately 4,000 cases per year. The condition is about three times more likely to occur in Caucasian babies compared to African-American babies, though the reasons for this difference are not entirely clear.^[3]

What Causes ABO Haemolytic Disease

The root cause of ABO haemolytic disease lies in the fundamental differences in blood types between mother and baby. Everyone has a blood type determined by the presence or absence of certain proteins, called antigens, on the surface of their red blood cells. The ABO blood group system categorizes blood into four main types: A, B, AB, and O. These antigens are widespread in nature and appear on many different types of cells throughout the body, not just red blood cells.^[2]

The disease develops through different pathways, but the most common involves what scientists call “environmental exposure.” Throughout life, people are naturally exposed to A and B antigens in their environment through various sources. This exposure usually triggers the production of IgM antibodies, which don’t cause problems during pregnancy because they’re too large to cross the placenta. However, some mothers naturally produce IgG antibodies instead, and these smaller antibodies can pass through the placental barrier and reach the baby’s bloodstream.^[2]

Another way mothers can develop these problematic antibodies is through fetal-maternal transfusion, where small amounts of the baby’s blood cross into the mother’s circulation. For example, when a mother with blood type O (genotype OO) carries a baby with blood type A (genotype AO), inherited from a father with blood type A or AB, her immune system may recognize the baby’s A antigens as foreign. Her body then produces IgG anti-A antibodies as a defense response.^[2]

It’s worth noting that blood transfusions very rarely cause ABO sensitization because medical professionals take great care to ensure that donated blood is ABO compatible with the recipient. Multiple checks and verification steps are performed to prevent such mismatches.^[2]

Risk Factors for Developing ABO HDN

Not every pregnancy with ABO incompatibility results in hemolytic disease. In fact, in about one-third of all ABO incompatible pregnancies, maternal IgG anti-A or anti-B antibodies do pass through the placenta to the baby’s circulation. This crossing of antibodies leads to what doctors call a weakly positive direct Coombs test when they examine the newborn’s blood. However, this doesn’t automatically mean the baby will develop significant illness.^[2]

There are several reasons why ABO HDN is generally mild and short-lived, even when antibodies are present. First, when IgG anti-A or anti-B antibodies enter the baby’s circulation from the mother, they encounter A or B antigens on many different types of fetal cells throughout the body, not just on red blood cells. This means the antibodies get spread out and attached to various cells, leaving fewer antibodies available to attack the red blood cells specifically.^[2]

Additionally, during fetal development, the A and B antigens on red blood cell surfaces are not fully developed. The baby’s red blood cells have fewer antigenic sites compared to adult red blood cells, which means there are simply fewer targets for the maternal antibodies to attack. This incomplete development of antigens provides a natural protective factor that helps limit the severity of the disease.^[2]

The primary risk factor for ABO HDN is having a mother with type O blood and a baby with type A, B, or AB blood. Mothers with type O blood naturally have both anti-A and anti-B antibodies in their blood, and when these are of the IgG subclass, they pose a risk to babies with A, B, or AB blood types. The father’s blood type plays a role too, as he must have type A, B, or AB blood to pass these antigens to the baby.^[2]

Recognizing the Symptoms

The symptoms of ABO haemolytic disease can vary considerably from one baby to another. During pregnancy, the mother typically experiences no symptoms at all. The condition is silent from her perspective, which is why medical testing is so important for detection. However, during prenatal ultrasound examinations or other tests, healthcare providers may notice signs such as yellowing of the amniotic fluid, abnormal fluid accumulation in the baby’s body, or enlargement of the baby’s liver or spleen.^[3]

After birth, affected babies may show several telltale signs. One of the most noticeable is pale skin, which results from anemia—a condition where the baby doesn’t have enough red blood cells to carry oxygen throughout the body. When the body’s organs and tissues can’t get enough oxygen, they struggle to function properly, which can cause the baby to become lethargic or unusually tired.^[3]

Yellowing of the skin and eyes, known as jaundice, is another common symptom. This happens because when red blood cells break down, they release a brownish-yellow substance called bilirubin. Newborn babies, especially those with hemolytic disease, have difficulty processing and eliminating bilirubin from their bodies. As bilirubin builds up in the blood—a condition called hyperbilirubinemia—it causes the characteristic yellow coloring of the skin, eyes, and even the umbilical cord.^[3]

In more severe cases, babies may develop an enlarged liver or spleen. This happens because the baby’s body tries to compensate for the rapid destruction of red blood cells by making new ones very quickly. The liver and spleen, which are involved in blood cell production, work overtime and become swollen as a result. Unfortunately, these newly produced red blood cells are often immature and can’t function properly, which means the anemia persists or worsens despite the body’s attempts to fix the problem.^[3]

When the baby’s body simply cannot cope with the severe anemia, a dangerous condition called hydrops fetalis can develop. In this situation, the baby’s heart begins to fail, and large amounts of fluid build up in tissues and organs throughout the body. This fluid accumulation can occur in the spaces around the lungs, heart, and abdominal organs, making it difficult for the baby to breathe and for the heart to pump effectively. If left untreated, this can lead to respiratory failure or heart failure.^[3]

Prevention Strategies

Unfortunately, routine antenatal antibody screening blood tests, which use what’s called an indirect Coombs test, do not screen specifically for ABO HDN. If IgG anti-A or anti-B antibodies are detected in a pregnant woman’s blood during routine testing, they are generally not reported to the doctor or flagged as a concern. This is different from Rh disease, where screening and prevention protocols are well established.^[2]

The good news is that ABO incompatibility typically follows a milder course than Rh disease and usually doesn’t require the same kind of preventive treatment. Unlike Rh disease, for which mothers receive prophylactic immunoglobulin injections (RhoGAM) to prevent sensitization, there is no similar preventive medication available for ABO incompatibility. The condition generally must be monitored and treated after birth if symptoms develop.^[1]

While specific prevention isn’t possible for ABO HDN, being aware of blood type incompatibilities can help healthcare providers prepare for potential complications. If a mother knows she has type O blood and the father has type A, B, or AB blood, healthcare providers can be ready to monitor the newborn closely for signs of hemolytic disease immediately after birth. This preparedness allows for early intervention if needed.^[4]

How the Disease Affects the Body

To understand how ABO haemolytic disease affects a newborn’s body, it helps to understand what happens when the condition develops. During pregnancy, if a fetus inherits blood group factors from the father that the mother doesn’t have, small amounts of the baby’s blood can cross into the mother’s circulation. This mixing can happen during delivery when the placenta separates, but it can also occur earlier during pregnancy, particularly during events like miscarriage, falls, or invasive prenatal testing procedures such as amniocentesis.^[1]

When the mother’s immune system encounters these foreign blood cells, it responds much like it would to bacteria or other invaders. The immune system produces antibodies designed to attack and destroy these foreign cells. In the case of ABO incompatibility, if a mother with type O blood encounters fetal cells with A or B antigens, her immune system may produce IgG antibodies against these antigens. Because IgG antibodies are relatively small molecules, they can cross the placental barrier and enter the baby’s bloodstream.^[4]

Once in the baby’s circulation, these maternal antibodies attach to the baby’s red blood cells and mark them for destruction. The baby’s own immune system then breaks down these tagged red blood cells in a process called hemolysis. This destruction happens much faster than normal, preventing the red blood cells from completing their usual 120-day lifespan. As red blood cells are destroyed, the baby develops anemia, meaning there aren’t enough red blood cells to carry oxygen throughout the body.^[4]

The breakdown of red blood cells releases bilirubin into the bloodstream. Bilirubin is a waste product that normally gets processed by the liver and eliminated from the body. However, newborn babies, especially those experiencing rapid red blood cell destruction, have immature liver systems that struggle to process bilirubin quickly enough. As bilirubin accumulates in the blood, it causes the yellowing of skin and eyes characteristic of jaundice. If levels get too high, bilirubin can even deposit in tissues throughout the body, including the brain, where it can cause permanent damage.^[3]

The baby’s body attempts to compensate for the loss of red blood cells by ramping up production of new ones. The liver and spleen, which are involved in blood cell production, work overtime and become enlarged as a result. However, in their rush to produce new cells, the body often creates immature red blood cells that don’t function as well as mature ones. These immature cells, sometimes called erythroblasts, can’t effectively carry oxygen, so despite increased production, the baby’s anemia may persist or even worsen.^[3]

In severe cases, the combination of anemia and the body’s attempts to compensate can lead to heart strain and failure. When the heart can no longer pump effectively, fluid begins to leak out of blood vessels and accumulate in tissues throughout the body. This fluid buildup, called hydrops fetalis when it occurs before birth, can compress the lungs and other organs, creating a life-threatening situation that requires immediate medical intervention.^[4]

Newborns with hemolytic disease may also develop other complications beyond the primary effects on red blood cells. These can include low blood sugar (hypoglycemia), low calcium levels (hypocalcemia), high potassium levels (hyperkalemia), and even kidney problems. Some babies may also develop low platelet counts (thrombocytopenia) or low white blood cell counts (neutropenia), which can affect blood clotting and immune function respectively. All of these metabolic disturbances require careful monitoring and correction to achieve the best outcomes.^[2]